S-ISOMER KETAMIN

Descripción Del Producto

S-Isomer Ketamine $((2S)\text{-2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one hydrochloride})$, commonly referred to as esketamine, is the isolated pharmacologically active $(S)\text{-(+)}$ optical isomer of racemic ketamine. In clinical pharmacodynamics and forensic chemistry, standardized analytical formulations of the S-enantiomer serve as crucial reference materials for studying rapid-acting glutamatergic neurotransmission, synaptic plasticity, and stereoselective drug metabolism.

Chemical & Pharmacodynamic Properties

• Molecular Formula & Mass: $\text{C}_{13}\text{H}_{16}\text{ClNO} \cdot \text{HCl}$ | 274.19 g/mol (hydrochloride salt)

• Receptor Mechanism of Action: Functions primarily as an uncompetitive, voltage-dependent channel blocker of open NMDA-type ionotropic glutamate receptors. By binding specifically to the phencyclidine (PCP) site within the ion channel pore, it reduces calcium ($\text{Ca}^{2+}$) and sodium ($\text{Na}^{+}$) influx.

• Synaptic Plasticity & Neurogenesis: NMDA inhibition leads to a transient disinhibition of GABAergic interneurons, causing a localized surge of glutamate that stimulates $\alpha$-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. This pathway triggers the release of brain-derived neurotrophic factor (BDNF) and activates the mammalian target of rapamycin (mTOR) signaling cascade, promoting rapid dendritic spine growth in the prefrontal cortex.

• Secondary Targets: Exhibits weak affinity for opioid $\mu$ y $\kappa$ receptors, monoamine transporters (dopamine, serotonin, norepinephrine), and sigma-1 receptors.

Clinical Applications & Pharmacokinetics

• Therapeutic Profile: The S-isomer is the active pharmaceutical ingredient in FDA-approved therapies for treatment-resistant depression (TRD) and major depressive disorder (MDD) with acute suicidal ideation, as well as an adjuvant in specialized surgical anesthesia and acute analgesia.

• Metabolism & Elimination: Rapidly metabolized in the liver primarily by CYP2B6 and CYP3A4 enzymes via $N$-demethylation to active $(S)\text{-norketamine}$, which retains approximately one-third of the parent compound’s NMDA receptor affinity. Demonstrates a terminal elimination half-life of roughly 2 to 4 hours with primary renal excretion.

Toxicological Risks & Regulatory Governance

• Clinical Safety Profile: Direct in vivo exposure carries risks of transient dissociative emergence reactions, perceptual alterations, marked blood pressure and heart rate elevation, cognitive sedation, and respiratory depression at anesthetic dosages. Chronic frequent exposure is associated with urinary tract toxicity, specifically ketamine-induced ulcerative cystitis.

• Controlled Substance Classification: In the United States, esketamine and ketamine salts are designated as Schedule III controlled substances under the Controlled Substances Act (Class B in the United Kingdom; Schedule II/IV internationally depending on jurisdiction). Procurement, custody, and disposal require appropriate institutional licensing, DEA registration, and hazardous chemical handling controls.